Literature DB >> 18985345

The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects.

Sargo Aalto1, Jussi Hirvonen, Valtteri Kaasinen, Nora Hagelberg, Jaana Kajander, Kjell Någren, Timo Seppälä, Juha O Rinne, Harry Scheinin, Jarmo Hietala.   

Abstract

PURPOSE: The dopamine D(2)/D(3) receptor ligand [(11)C]FLB 457 and PET enable quantification of low-density extrastriatal D(2)/D(3) receptors, but it is uncertain whether [(11)C]FLB 457 can be used for measuring extrastriatal dopamine release.
METHODS: We studied the effects of d-amphetamine (0.3 mg/kg i.v.) on extrastriatal [(11)C]FLB 457 binding potential (BP(ND)) in a randomized, double-blind, placebo-controlled study including 24 healthy volunteers.
RESULTS: The effects of d-amphetamine on [(11)C]FLB 457 BP(ND) and distribution volume (V(T)) in the frontal cortex were not different from those of placebo. Small decreases in [(11)C]FLB 457 BP(ND) were observed only in the posterior cingulate and hippocampus. The regional changes in [(11)C]FLB 457 BP(ND) did not correlate with d-amphetamine-induced changes in subjective ratings of euphoria.
CONCLUSION: This placebo-controlled study showed that d-amphetamine does not induce marked changes in measures of extrastriatal dopamine D(2)/D(3) receptor binding. Our results indicate that [(11)C]FLB 457 PET is not a useful method for measuring extrastriatal dopamine release in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18985345     DOI: 10.1007/s00259-008-0969-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  36 in total

1.  Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain.

Authors:  H Olsson; C Halldin; C G Swahn; L Farde
Journal:  J Cereb Blood Flow Metab       Date:  1999-10       Impact factor: 6.200

Review 2.  Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers.

Authors:  M Slifstein; M Laruelle
Journal:  Nucl Med Biol       Date:  2001-07       Impact factor: 2.408

3.  Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457.

Authors:  Sargo Aalto; Anna Brück; Matti Laine; Kjell Någren; Juha O Rinne
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

4.  Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C]FLB 457 PET.

Authors:  Andrew J Montgomery; Marie-Claude Asselin; Lars Farde; Paul M Grasby
Journal:  J Cereb Blood Flow Metab       Date:  2006-05-10       Impact factor: 6.200

Review 5.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

6.  Positron emission tomography displacement sensitivity: predicting binding potential change for positron emission tomography tracers based on their kinetic characteristics.

Authors:  Evan D Morris; Karmen K Yoder
Journal:  J Cereb Blood Flow Metab       Date:  2006-06-21       Impact factor: 6.200

7.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

Authors:  A Breier; T P Su; R Saunders; R E Carson; B S Kolachana; A de Bartolomeis; D R Weinberger; N Weisenfeld; A K Malhotra; W C Eckelman; D Pickar
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

8.  Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans.

Authors:  Patrizia Riccardi; Rui Li; Mohammad Sib Ansari; David Zald; Sohee Park; Benoit Dawant; Sharlet Anderson; Mikisha Doop; Neil Woodward; Evan Schoenberg; Dennis Schmidt; Ronald Baldwin; Robert Kessler
Journal:  Neuropsychopharmacology       Date:  2006-05       Impact factor: 7.853

9.  Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans.

Authors:  Vanessa L Cropley; Robert B Innis; Pradeep J Nathan; Amira K Brown; Janet L Sangare; Alicja Lerner; Yong Hoon Ryu; Kelly E Sprague; Victor W Pike; Masahiro Fujita
Journal:  Synapse       Date:  2008-06       Impact factor: 2.562

10.  Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine.

Authors:  B Adams; B Moghaddam
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

View more
  17 in total

Review 1.  Testing for radioligand sensitivity to endogenous neurotransmitter release.

Authors:  Gitte M Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

2.  Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride.

Authors:  Mark Slifstein; Lawrence S Kegeles; Xiaoyan Xu; Judy L Thompson; Nina Urban; John Castrillon; Elizabeth Hackett; S-A Bae; Marc Laruelle; Anissa Abi-Dargham
Journal:  Synapse       Date:  2010-05       Impact factor: 2.562

Review 3.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

4.  Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.

Authors:  Rajesh Narendran; N Scott Mason; Chi-Min Chen; Michael Himes; Patrick Keating; Maureen A May; Eugenii A Rabiner; Marc Laruelle; Chester A Mathis; W Gordon Frankle
Journal:  Synapse       Date:  2011-04-26       Impact factor: 2.562

5.  Failure to detect amphetamine-induced dopamine release in the cortex with [11 C]FLB 457 positron emission tomography (PET): Methodological considerations.

Authors:  Joshua Gertler; Savannah Tollefson; Rehima Jordan; Michael L Himes; N Scott Mason; W Gordon Frankle; Rajesh Narendran
Journal:  Synapse       Date:  2018-07-13       Impact factor: 2.562

Review 6.  Dopaminergic neurotransmission in the human brain: new lessons from perturbation and imaging.

Authors:  Ji Hyun Ko; Antonio P Strafella
Journal:  Neuroscientist       Date:  2011-05-02       Impact factor: 7.519

7.  Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers.

Authors:  Ningning Guo; Wen Guo; Michaela Kralikova; Man Jiang; Ira Schieren; Raj Narendran; Mark Slifstein; Anissa Abi-Dargham; Marc Laruelle; Jonathan A Javitch; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

8.  Thinking outside a less intact box: thalamic dopamine D2 receptor densities are negatively related to psychometric creativity in healthy individuals.

Authors:  Orjan de Manzano; Simon Cervenka; Anke Karabanov; Lars Farde; Fredrik Ullén
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

Review 9.  Neurofunctional imaging of β-cell dynamics.

Authors:  P E Harris; R L Leibel
Journal:  Diabetes Obes Metab       Date:  2012-10       Impact factor: 6.577

10.  COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor availability in vivo.

Authors:  Mika M Hirvonen; Kjell Någren; Juha O Rinne; Ullamari Pesonen; Tero Vahlberg; Nora Hagelberg; Jarmo Hietala
Journal:  Mol Imaging Biol       Date:  2009-10-01       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.